Why IGF-1 LR3 Is Inferior to HGH for Muscle Growth

Most people who use growth hormone eventually run into the same question. If growth hormone works by raising IGF-1, why not just inject IGF-1 directly and skip the middleman? And if you do use growth hormone, why not stack IGF-1 on top of it to amplify the effect? It sounds logical on the surface. But the biology of how IGF-1 actually works, where it comes from, and what happens when you flood your system with a synthetic version tells a very different story.

To understand why, you need to see the whole chain first. Growth hormone is released from the pituitary gland in pulses, travels through the bloodstream, and hits the liver. The liver responds by producing something called IGF-1, which stands for insulin-like growth factor 1, and that IGF-1 is one of the main downstream signals responsible for tissue growth, cell repair, and muscle protein synthesis. So the chain is simple: pituitary releases growth hormone, growth hormone tells the liver to make IGF-1, and IGF-1 goes out and does the actual building work at the cellular level.

But that is only one source of IGF-1. And that distinction is the entire crux of the problem.

When people inject exogenous growth hormone, their liver produces more IGF-1 systemically, meaning it circulates throughout the body. At the same time, and this is the part most people miss, growth hormone also stimulates local IGF-1 production directly inside muscle tissue. This locally produced IGF-1 acts in what scientists call an autocrine and paracrine fashion, meaning it works on the very cells that made it and on nearby cells without ever entering the general circulation. It is this local, muscle-derived IGF-1 that drives a large portion of the hypertrophy response to growth hormone because it acts right at the site where you need it most, directly on muscle fibers and their satellite cells.

So you have two pools of IGF-1 doing two different jobs. Liver-derived IGF-1 circulates systemically and supports general growth and recovery. Muscle-derived IGF-1 stays local and drives the actual process of adding contractile tissue. When growth hormone is the input, you get both.

This is where IGF-1 LR3 enters the picture, and it is a modified version of IGF-1 that has been engineered with an arginine substitution at position 3 and an additional 13 amino acids on the N-terminus, which reduces its binding affinity for IGF-binding proteins. Normally, circulating IGF-1 spends most of its time bound to carrier proteins, particularly something called IGFBP-3, which limits how much free IGF-1 is available to interact with receptors. The LR3 variant largely escapes that binding, which means it stays active in the bloodstream far longer than native IGF-1, and that is the whole appeal of using it, because people figure that since the native form of IGF-1 has a half-life measured in minutes when unbound, having a version that stays bioactive for roughly 20 to 30 hours should translate directly into more growth signaling. Why would I add IGF-1 LR-3 if I'm already taking HGH? Because the LR-3 extends the half-life of that drug.

More active IGF-1 floating around for longer should mean more growth signaling and more muscle, and on the surface that reasoning seems to hold up, but it runs into a wall once you understand what continuous receptor stimulation actually does to the cells receiving that signal. The problem with increasing your IGF-1 levels is it creates receptor desensitization. This is the same principle that applies to nearly every receptor-ligand system in the body. When a receptor is exposed to its signal molecule continuously, the cell begins to downregulate its response. It either reduces the number of receptors on the surface, internalizes them, or dampens the intracellular signaling cascade that would normally follow receptor activation. This process has been well characterized in analogous receptor systems. Research published in Frontiers in Physiology by Corbi and colleagues in 2013 described this exact dynamic in the context of adrenergic receptors, showing how chronic stimulation leads to oxidative stress and compensatory downregulation, a principle that applies broadly across receptor biology.

Meaning this IGF-1 is just gonna sit here and hammer the receptors on your cells. When you inject IGF-1 LR3, you are not delivering a pulsed signal the way the body naturally produces IGF-1 in response to growth hormone. You are delivering a sustained, high-concentration flood of a ligand that will not clear quickly because it evades the binding proteins designed to regulate its activity. The receptors on target cells are being activated continuously, hour after hour, and the cell's natural defense against that kind of overstimulation is to reduce its sensitivity. The signal gets louder, so the cell turns down the volume.

And so because IGF-1 is creating that desensitization on the cell or the receptors, it doesn't make sense to use long-term. Over days and weeks, what initially looked like a stronger growth signal becomes a progressively weaker one because the receptors themselves are no longer responding at full capacity. You are spending money and adding complexity to a protocol for diminishing returns, and potentially making yourself less responsive to your own endogenous IGF-1 in the process.

This raises the obvious question: if the goal is more IGF-1 signaling, why not just let the body make it? Why would I use something that's creating suppression when I can just go up the chain, do the growth hormone, and my body will produce as much IGF-1 as I want? But here's the other piece, okay? IGF-1 isn't just produced at the liver. It is also produced inside of the muscles. And this is where the argument against exogenous IGF-1 gets even stronger.

When you administer growth hormone, your liver increases systemic IGF-1 output, but your muscle tissue also ramps up its own local production of IGF-1. This locally synthesized IGF-1 acts directly on muscle fibers and their surrounding satellite cells, stimulating protein synthesis and promoting the incorporation of new nuclei into existing muscle fibers, a process that is fundamental to long-term hypertrophy. Because this IGF-1 is produced inside the muscle itself, it does not need to travel through the bloodstream, it does not compete with binding proteins for access, and it acts at concentrations that are precisely tuned to the local demand created by training and recovery.

When you inject exogenous IGF-1 LR3, something important happens to this local system. Elevated circulating IGF-1 feeds back on the growth hormone axis. It suppresses pituitary release of growth hormone through negative feedback, which means less growth hormone reaching the muscles, which means less stimulation for the muscles to produce their own IGF-1. And when we inject the IGF-1 LR-3, we lose out on the, we'll say, muscle-producing IGF-1. You are effectively trading a high-quality local signal for a lower-quality systemic one. The injected IGF-1 LR3 circulates everywhere, hammering receptors indiscriminately and causing desensitization, while the specific, targeted IGF-1 production inside the muscle that would have been triggered by growth hormone is now diminished because the growth hormone signal itself has been blunted.

And when that happens, now you're putting yourself in a situation where you're actually losing most of the muscle-gaining benefits that you would otherwise get if you just used the growth hormone. The irony is that people add IGF-1 LR3 to their growth hormone protocol thinking they are enhancing the anabolic effect, when the net result is often a reduction in the specific type of IGF-1 signaling that matters most for muscle growth, all while introducing receptor desensitization that makes the remaining signal less effective.

This is not a theoretical concern limited to receptor biology either. The broader principle of negative feedback in the growth hormone axis is well established. Elevated IGF-1 levels directly inhibit growth hormone releasing hormone at the hypothalamus and stimulate somatostatin release, which further suppresses growth hormone secretion. So the more exogenous IGF-1 you add, the less growth hormone your body produces, and the less local muscle IGF-1 you get as a consequence. It is a trade that works against you on multiple levels simultaneously.

What people actually get when they stack IGF-1 LR3 on top of growth hormone is not two growth signals running in parallel but rather a blunt instrument replacing a precise, self-regulating system, and that instrument creates tolerance, suppresses the very axis you are trying to optimize, and shifts IGF-1 activity away from muscle tissue and into systemic circulation where it does less of what you actually want. Growth hormone alone gives you both the systemic and the local signal. Adding exogenous IGF-1 collapses that dual system into a single, desensitizing, feedback-disrupting input.

The whole framework people use to justify stacking IGF-1 on top of growth hormone is built on the assumption that more of the signal molecule means more of the effect, and that assumption falls apart once you look at how receptor systems actually respond to prolonged stimulation, because the body does not simply tally up molecules and convert them into proportional output. It counts how long those molecules are there, where they are, and whether the receptors they bind to are still listening. When the receptors stop listening, more molecules is just noise.

References:

Corbi G, Conti V, Russomanno G et al.. Adrenergic signaling and oxidative stress: a role for sirtuins? Front Physiol. 2013. https://pubmed.ncbi.nlm.nih.gov/24265619/